Drug search by name

Carfilzomib Intravenous and Hepatic toxicity

Result of checking the interaction of drug Carfilzomib Intravenous and disease Hepatic toxicity for safety when used together.

Check result:

Carfilzomib Intravenous <> Hepatic toxicity

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Cases of hepatic failure, including fatal cases, have been reported in patients receiving treatment with carfilzomib. The pharmacokinetics and safety of carfilzomib were evaluated in patients with normal hepatic function, or mild, moderate, or severe hepatic impairment. The AUC of carfilzomib increased by approximately 50% in patients with mild and moderate hepatic impairment compared to patients with normal hepatic function. PK data were not collected in patients with severe hepatic impairment. It is recommended to reduce the dose of carfilzomib by 25% in patients with mild or moderate hepatic impairment. Dosing recommendation cannot be made for patients with severe hepatic function. Monitor liver enzymes regularly, regardless of baseline values, and modify dose based on toxicity. Therapy with this agent can cause increased serum transaminases. Monitor liver enzymes regularly, regardless of baseline values. It is recommended to reduce or withhold dose as appropriate.

Carfilzomib Intravenous

Generic Name: carfilzomib

Brand Name: Kyprolis

Synonyms: Carfilzomib

What is Carfilzomib Intravenous?